Subcutaneous Infusion Devices Comprehensive Study by Type (Insulin Infusion Pumps, Pen injectors, Auto-injectors, Wearable injectors, Needle-free Injectors, Others), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Usage (Disposable, Reusable), End Use (Diabetes, RA, MS, Others) Players and Region - Global Market Outlook to 2027

Subcutaneous Infusion Devices Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 10.5%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Subcutaneous Infusion Devices Market Overview:
A subcutaneous injection is given as a bolus into the subcutis, the layer of skin directly beneath the dermis and epidermis, also known as the cutis. A hypodermic needle and a syringe are typically used. Subcutaneous injections are an excellent way to administer medications such as insulin, morphine, diacetylmorphine, and goserelin. SC, SQ, subcu, sub-Q, SubQ, or subcut are all abbreviations for subcutaneous administration. Subcut is the preferred abbreviation to reduce the possibility of misunderstanding and errors. Because subcutaneous tissue has few blood vessels, drugs injected here are designed for slow, sustained absorption, often with some depot effect. It is slower than intramuscular injections but faster than intradermal injections when compared to other routes of administration. As per latest study released by AMA Research, the Global Subcutaneous Infusion Devices market is expected to see growth rate of 10.5%

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Billion)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Growth Drivers
  • The Rising Healthcare Expenditure Related to Diabetes and Favourable Reimbursement Policies for Insulin Pumps are Driving the Growth of the Continuous Subcutaneous Infusion Devices Market.

Roadblocks
  • The lack Of Approved Product In The Subcutaneous Infusion Delivery Device Market Is Restraints In This Market.

Opportunities
  • The Increasing Penetration of the Smart Insulin Pump Has Brought Major Opportunities to the Market.

Challenges
  • The Less Blood Flow through Subcutaneous Infusion Delivery Devices Results in Slow Absorption of Drugs.


Competitive Landscape:
Market players are focusing on providing Subcutaneous Infusion Devices with higher quality along with complying with all regulatory standards to fascinate more end users. They are also focusing on the introduction of numerous advanced & attractive features to further offer qualified Subcutaneous Infusion Devices. Besides, the numerous industry profitability has led to the entry of new players, in turn, increasing the level of rivalry in the already competitive market.
Some of the key players profiled in the report are Gerresheimer AG (Germany), Medtronic Plc (Ireland), Ypsomed AG (Switzerland), Elcam Medical Group (Israel), Novo Nordisk (Denmark), Insulet Corporation (United States), Becton, Dickinson and Company (United States), West Pharmaceutical Services, Inc. (United States), PharmaJet (United States) and Unilife Corporation (United States). Additionally, following companies can also be profiled that are part of our coverage like Inolife Sciences (Canada), Cellnovo (United Kingdom), Owen Mumford (United Kingdom), Roche (Switzerland), Mitsubishi Tanabe Pharma (Neuroderm) (Japan), Supernus (United States) and AbbVie (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Subcutaneous Infusion Devices market by 2027. Considering Market by Usage, the sub-segment i.e. Disposable will boost the Subcutaneous Infusion Devices market. Considering Market by End Use, the sub-segment i.e. Diabetes will boost the Subcutaneous Infusion Devices market.

Latest Market Insights:
In November 2021, Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector. The go-to-market approach for the autoinjector combines the complementary strengths of both companies - Gerresheimer as a solution provider for medical devices and primary packaging solutions and Midas Pharma as experienced facilitator for global pharma projects and provider of products and services along the pharmaceutical value chain.

In December 2021, Gerresheimer has entered into an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer's innovative strength and engineering expertise for the development of a new pump to deliver a leading drug for the treatment of rare diseases via continuous parenteral administration.

Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a device that has been found substantially equivalent to such a device, has an approval under section 515 of the act FDA must promulgate a regulation under section 515(b) of the act requiring such approval, except as provided in paragraph (b) of this section. Such a regulation under section 515(b) of the act shall not be effective during the grace period ending on the 90th day after its promulgation or on the last day of the 30th full calendar month after the regulation that classifies the device into class III is effective, whichever is later.

What Can be Explored with the Subcutaneous Infusion Devices Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Subcutaneous Infusion Devices Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Subcutaneous Infusion Devices
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Subcutaneous Infusion Devices market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Subcutaneous Infusion Devices market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceutical companies, Medical instruments Manufacturers, Hospitals and Healthcare facilities, New Entrants and Investors, Legalized Cannabis Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Insulin Infusion Pumps
  • Pen injectors
  • Auto-injectors
  • Wearable injectors
  • Needle-free Injectors
  • Others
By Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Usage
  • Disposable
  • Reusable

By End Use
  • Diabetes
  • RA
  • MS
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Healthcare Expenditure Related to Diabetes and Favourable Reimbursement Policies for Insulin Pumps are Driving the Growth of the Continuous Subcutaneous Infusion Devices Market.
    • 3.3. Market Challenges
      • 3.3.1. The Less Blood Flow through Subcutaneous Infusion Delivery Devices Results in Slow Absorption of Drugs.
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements Including AI and the Internet of Things (IoT) are also Boosting the Demand for Continuous Subcutaneous Infusion Devices.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Subcutaneous Infusion Devices, by Type, Application, Usage, End Use and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Subcutaneous Infusion Devices (Value)
      • 5.2.1. Global Subcutaneous Infusion Devices by: Type (Value)
        • 5.2.1.1. Insulin Infusion Pumps
        • 5.2.1.2. Pen injectors
        • 5.2.1.3. Auto-injectors
        • 5.2.1.4. Wearable injectors
        • 5.2.1.5. Needle-free Injectors
        • 5.2.1.6. Others
      • 5.2.2. Global Subcutaneous Infusion Devices by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Subcutaneous Infusion Devices by: Usage (Value)
        • 5.2.3.1. Disposable
        • 5.2.3.2. Reusable
      • 5.2.4. Global Subcutaneous Infusion Devices by: End Use (Value)
        • 5.2.4.1. Diabetes
        • 5.2.4.2. RA
        • 5.2.4.3. MS
        • 5.2.4.4. Others
      • 5.2.5. Global Subcutaneous Infusion Devices Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Spain
          • 5.2.5.3.4. Italy
          • 5.2.5.3.5. United Kingdom
          • 5.2.5.3.6. Netherlands
          • 5.2.5.3.7. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Subcutaneous Infusion Devices (Price)
      • 5.3.1. Global Subcutaneous Infusion Devices by: Type (Price)
  • 6. Subcutaneous Infusion Devices: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gerresheimer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medtronic Plc (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ypsomed AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Elcam Medical Group (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Insulet Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton, Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. West Pharmaceutical Services, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. PharmaJet (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Unilife Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Subcutaneous Infusion Devices Sale, by Type, Application, Usage, End Use and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Subcutaneous Infusion Devices (Value)
      • 7.2.1. Global Subcutaneous Infusion Devices by: Type (Value)
        • 7.2.1.1. Insulin Infusion Pumps
        • 7.2.1.2. Pen injectors
        • 7.2.1.3. Auto-injectors
        • 7.2.1.4. Wearable injectors
        • 7.2.1.5. Needle-free Injectors
        • 7.2.1.6. Others
      • 7.2.2. Global Subcutaneous Infusion Devices by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Subcutaneous Infusion Devices by: Usage (Value)
        • 7.2.3.1. Disposable
        • 7.2.3.2. Reusable
      • 7.2.4. Global Subcutaneous Infusion Devices by: End Use (Value)
        • 7.2.4.1. Diabetes
        • 7.2.4.2. RA
        • 7.2.4.3. MS
        • 7.2.4.4. Others
      • 7.2.5. Global Subcutaneous Infusion Devices Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Spain
          • 7.2.5.3.4. Italy
          • 7.2.5.3.5. United Kingdom
          • 7.2.5.3.6. Netherlands
          • 7.2.5.3.7. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Subcutaneous Infusion Devices (Price)
      • 7.3.1. Global Subcutaneous Infusion Devices by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Subcutaneous Infusion Devices: by Type(USD Billion)
  • Table 2. Subcutaneous Infusion Devices Insulin Infusion Pumps , by Region USD Billion (2016-2021)
  • Table 3. Subcutaneous Infusion Devices Pen injectors , by Region USD Billion (2016-2021)
  • Table 4. Subcutaneous Infusion Devices Auto-injectors , by Region USD Billion (2016-2021)
  • Table 5. Subcutaneous Infusion Devices Wearable injectors , by Region USD Billion (2016-2021)
  • Table 6. Subcutaneous Infusion Devices Needle-free Injectors , by Region USD Billion (2016-2021)
  • Table 7. Subcutaneous Infusion Devices Others , by Region USD Billion (2016-2021)
  • Table 8. Subcutaneous Infusion Devices: by Application(USD Billion)
  • Table 9. Subcutaneous Infusion Devices Hospital Pharmacies , by Region USD Billion (2016-2021)
  • Table 10. Subcutaneous Infusion Devices Retail Pharmacies , by Region USD Billion (2016-2021)
  • Table 11. Subcutaneous Infusion Devices Online Pharmacies , by Region USD Billion (2016-2021)
  • Table 12. Subcutaneous Infusion Devices: by Usage(USD Billion)
  • Table 13. Subcutaneous Infusion Devices Disposable , by Region USD Billion (2016-2021)
  • Table 14. Subcutaneous Infusion Devices Reusable , by Region USD Billion (2016-2021)
  • Table 15. Subcutaneous Infusion Devices: by End Use(USD Billion)
  • Table 16. Subcutaneous Infusion Devices Diabetes , by Region USD Billion (2016-2021)
  • Table 17. Subcutaneous Infusion Devices RA , by Region USD Billion (2016-2021)
  • Table 18. Subcutaneous Infusion Devices MS , by Region USD Billion (2016-2021)
  • Table 19. Subcutaneous Infusion Devices Others , by Region USD Billion (2016-2021)
  • Table 20. South America Subcutaneous Infusion Devices, by Country USD Billion (2016-2021)
  • Table 21. South America Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 22. South America Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 23. South America Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 24. South America Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 25. Brazil Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 26. Brazil Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 27. Brazil Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 28. Brazil Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 29. Argentina Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 30. Argentina Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 31. Argentina Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 32. Argentina Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 33. Rest of South America Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 34. Rest of South America Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 35. Rest of South America Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 36. Rest of South America Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 37. Asia Pacific Subcutaneous Infusion Devices, by Country USD Billion (2016-2021)
  • Table 38. Asia Pacific Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 39. Asia Pacific Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 40. Asia Pacific Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 41. Asia Pacific Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 42. China Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 43. China Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 44. China Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 45. China Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 46. Japan Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 47. Japan Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 48. Japan Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 49. Japan Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 50. India Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 51. India Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 52. India Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 53. India Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 54. South Korea Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 55. South Korea Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 56. South Korea Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 57. South Korea Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 58. Australia Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 59. Australia Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 60. Australia Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 61. Australia Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 62. Rest of Asia-Pacific Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 63. Rest of Asia-Pacific Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 64. Rest of Asia-Pacific Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 65. Rest of Asia-Pacific Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 66. Europe Subcutaneous Infusion Devices, by Country USD Billion (2016-2021)
  • Table 67. Europe Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 68. Europe Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 69. Europe Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 70. Europe Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 71. Germany Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 72. Germany Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 73. Germany Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 74. Germany Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 75. France Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 76. France Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 77. France Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 78. France Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 79. Spain Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 80. Spain Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 81. Spain Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 82. Spain Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 83. Italy Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 84. Italy Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 85. Italy Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 86. Italy Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 87. United Kingdom Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 88. United Kingdom Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 89. United Kingdom Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 90. United Kingdom Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 91. Netherlands Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 92. Netherlands Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 93. Netherlands Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 94. Netherlands Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 95. Rest of Europe Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 96. Rest of Europe Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 97. Rest of Europe Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 98. Rest of Europe Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 99. MEA Subcutaneous Infusion Devices, by Country USD Billion (2016-2021)
  • Table 100. MEA Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 101. MEA Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 102. MEA Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 103. MEA Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 104. Middle East Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 105. Middle East Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 106. Middle East Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 107. Middle East Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 108. Africa Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 109. Africa Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 110. Africa Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 111. Africa Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 112. North America Subcutaneous Infusion Devices, by Country USD Billion (2016-2021)
  • Table 113. North America Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 114. North America Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 115. North America Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 116. North America Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 117. United States Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 118. United States Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 119. United States Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 120. United States Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 121. Canada Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 122. Canada Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 123. Canada Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 124. Canada Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 125. Mexico Subcutaneous Infusion Devices, by Type USD Billion (2016-2021)
  • Table 126. Mexico Subcutaneous Infusion Devices, by Application USD Billion (2016-2021)
  • Table 127. Mexico Subcutaneous Infusion Devices, by Usage USD Billion (2016-2021)
  • Table 128. Mexico Subcutaneous Infusion Devices, by End Use USD Billion (2016-2021)
  • Table 129. Subcutaneous Infusion Devices: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Subcutaneous Infusion Devices: by Type(USD Billion)
  • Table 141. Subcutaneous Infusion Devices Insulin Infusion Pumps , by Region USD Billion (2022-2027)
  • Table 142. Subcutaneous Infusion Devices Pen injectors , by Region USD Billion (2022-2027)
  • Table 143. Subcutaneous Infusion Devices Auto-injectors , by Region USD Billion (2022-2027)
  • Table 144. Subcutaneous Infusion Devices Wearable injectors , by Region USD Billion (2022-2027)
  • Table 145. Subcutaneous Infusion Devices Needle-free Injectors , by Region USD Billion (2022-2027)
  • Table 146. Subcutaneous Infusion Devices Others , by Region USD Billion (2022-2027)
  • Table 147. Subcutaneous Infusion Devices: by Application(USD Billion)
  • Table 148. Subcutaneous Infusion Devices Hospital Pharmacies , by Region USD Billion (2022-2027)
  • Table 149. Subcutaneous Infusion Devices Retail Pharmacies , by Region USD Billion (2022-2027)
  • Table 150. Subcutaneous Infusion Devices Online Pharmacies , by Region USD Billion (2022-2027)
  • Table 151. Subcutaneous Infusion Devices: by Usage(USD Billion)
  • Table 152. Subcutaneous Infusion Devices Disposable , by Region USD Billion (2022-2027)
  • Table 153. Subcutaneous Infusion Devices Reusable , by Region USD Billion (2022-2027)
  • Table 154. Subcutaneous Infusion Devices: by End Use(USD Billion)
  • Table 155. Subcutaneous Infusion Devices Diabetes , by Region USD Billion (2022-2027)
  • Table 156. Subcutaneous Infusion Devices RA , by Region USD Billion (2022-2027)
  • Table 157. Subcutaneous Infusion Devices MS , by Region USD Billion (2022-2027)
  • Table 158. Subcutaneous Infusion Devices Others , by Region USD Billion (2022-2027)
  • Table 159. South America Subcutaneous Infusion Devices, by Country USD Billion (2022-2027)
  • Table 160. South America Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 161. South America Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 162. South America Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 163. South America Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 164. Brazil Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 165. Brazil Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 166. Brazil Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 167. Brazil Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 168. Argentina Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 169. Argentina Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 170. Argentina Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 171. Argentina Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 172. Rest of South America Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 173. Rest of South America Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 174. Rest of South America Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 175. Rest of South America Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 176. Asia Pacific Subcutaneous Infusion Devices, by Country USD Billion (2022-2027)
  • Table 177. Asia Pacific Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 178. Asia Pacific Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 179. Asia Pacific Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 180. Asia Pacific Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 181. China Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 182. China Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 183. China Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 184. China Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 185. Japan Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 186. Japan Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 187. Japan Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 188. Japan Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 189. India Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 190. India Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 191. India Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 192. India Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 193. South Korea Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 194. South Korea Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 195. South Korea Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 196. South Korea Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 197. Australia Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 198. Australia Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 199. Australia Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 200. Australia Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 201. Rest of Asia-Pacific Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 202. Rest of Asia-Pacific Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 203. Rest of Asia-Pacific Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 204. Rest of Asia-Pacific Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 205. Europe Subcutaneous Infusion Devices, by Country USD Billion (2022-2027)
  • Table 206. Europe Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 207. Europe Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 208. Europe Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 209. Europe Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 210. Germany Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 211. Germany Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 212. Germany Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 213. Germany Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 214. France Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 215. France Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 216. France Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 217. France Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 218. Spain Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 219. Spain Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 220. Spain Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 221. Spain Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 222. Italy Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 223. Italy Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 224. Italy Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 225. Italy Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 226. United Kingdom Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 227. United Kingdom Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 228. United Kingdom Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 229. United Kingdom Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 230. Netherlands Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 231. Netherlands Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 232. Netherlands Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 233. Netherlands Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 234. Rest of Europe Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 235. Rest of Europe Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 236. Rest of Europe Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 237. Rest of Europe Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 238. MEA Subcutaneous Infusion Devices, by Country USD Billion (2022-2027)
  • Table 239. MEA Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 240. MEA Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 241. MEA Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 242. MEA Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 243. Middle East Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 244. Middle East Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 245. Middle East Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 246. Middle East Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 247. Africa Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 248. Africa Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 249. Africa Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 250. Africa Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 251. North America Subcutaneous Infusion Devices, by Country USD Billion (2022-2027)
  • Table 252. North America Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 253. North America Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 254. North America Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 255. North America Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 256. United States Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 257. United States Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 258. United States Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 259. United States Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 260. Canada Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 261. Canada Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 262. Canada Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 263. Canada Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 264. Mexico Subcutaneous Infusion Devices, by Type USD Billion (2022-2027)
  • Table 265. Mexico Subcutaneous Infusion Devices, by Application USD Billion (2022-2027)
  • Table 266. Mexico Subcutaneous Infusion Devices, by Usage USD Billion (2022-2027)
  • Table 267. Mexico Subcutaneous Infusion Devices, by End Use USD Billion (2022-2027)
  • Table 268. Subcutaneous Infusion Devices: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Subcutaneous Infusion Devices: by Type USD Billion (2016-2021)
  • Figure 5. Global Subcutaneous Infusion Devices: by Application USD Billion (2016-2021)
  • Figure 6. Global Subcutaneous Infusion Devices: by Usage USD Billion (2016-2021)
  • Figure 7. Global Subcutaneous Infusion Devices: by End Use USD Billion (2016-2021)
  • Figure 8. South America Subcutaneous Infusion Devices Share (%), by Country
  • Figure 9. Asia Pacific Subcutaneous Infusion Devices Share (%), by Country
  • Figure 10. Europe Subcutaneous Infusion Devices Share (%), by Country
  • Figure 11. MEA Subcutaneous Infusion Devices Share (%), by Country
  • Figure 12. North America Subcutaneous Infusion Devices Share (%), by Country
  • Figure 13. Global Subcutaneous Infusion Devices: by Type USD/Units (2016-2021)
  • Figure 14. Global Subcutaneous Infusion Devices share by Players 2021 (%)
  • Figure 15. Global Subcutaneous Infusion Devices share by Players (Top 3) 2021(%)
  • Figure 16. Global Subcutaneous Infusion Devices share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Gerresheimer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Gerresheimer AG (Germany) Revenue: by Geography 2021
  • Figure 20. Medtronic Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Medtronic Plc (Ireland) Revenue: by Geography 2021
  • Figure 22. Ypsomed AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Ypsomed AG (Switzerland) Revenue: by Geography 2021
  • Figure 24. Elcam Medical Group (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Elcam Medical Group (Israel) Revenue: by Geography 2021
  • Figure 26. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 27. Novo Nordisk (Denmark) Revenue: by Geography 2021
  • Figure 28. Insulet Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Insulet Corporation (United States) Revenue: by Geography 2021
  • Figure 30. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Becton, Dickinson and Company (United States) Revenue: by Geography 2021
  • Figure 32. West Pharmaceutical Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. West Pharmaceutical Services, Inc. (United States) Revenue: by Geography 2021
  • Figure 34. PharmaJet (United States) Revenue, Net Income and Gross profit
  • Figure 35. PharmaJet (United States) Revenue: by Geography 2021
  • Figure 36. Unilife Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 37. Unilife Corporation (United States) Revenue: by Geography 2021
  • Figure 38. Global Subcutaneous Infusion Devices: by Type USD Billion (2022-2027)
  • Figure 39. Global Subcutaneous Infusion Devices: by Application USD Billion (2022-2027)
  • Figure 40. Global Subcutaneous Infusion Devices: by Usage USD Billion (2022-2027)
  • Figure 41. Global Subcutaneous Infusion Devices: by End Use USD Billion (2022-2027)
  • Figure 42. South America Subcutaneous Infusion Devices Share (%), by Country
  • Figure 43. Asia Pacific Subcutaneous Infusion Devices Share (%), by Country
  • Figure 44. Europe Subcutaneous Infusion Devices Share (%), by Country
  • Figure 45. MEA Subcutaneous Infusion Devices Share (%), by Country
  • Figure 46. North America Subcutaneous Infusion Devices Share (%), by Country
  • Figure 47. Global Subcutaneous Infusion Devices: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Gerresheimer AG (Germany)
  • Medtronic Plc (Ireland)
  • Ypsomed AG (Switzerland)
  • Elcam Medical Group (Israel)
  • Novo Nordisk (Denmark)
  • Insulet Corporation (United States)
  • Becton, Dickinson and Company (United States)
  • West Pharmaceutical Services, Inc. (United States)
  • PharmaJet (United States)
  • Unilife Corporation (United States)
Additional players considered in the study are as follows:
Inolife Sciences (Canada) , Cellnovo (United Kingdom) , Owen Mumford (United Kingdom) , Roche (Switzerland) , Mitsubishi Tanabe Pharma (Neuroderm) (Japan) , Supernus (United States) , AbbVie (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 202 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Subcutaneous Infusion Devices market are Gerresheimer AG (Germany), Medtronic Plc (Ireland), Ypsomed AG (Switzerland), Elcam Medical Group (Israel), Novo Nordisk (Denmark), Insulet Corporation (United States), Becton, Dickinson and Company (United States), West Pharmaceutical Services, Inc. (United States), PharmaJet (United States) and Unilife Corporation (United States), to name a few.
"Technological Advancements Including AI and the Internet of Things (IoT) are also Boosting the Demand for Continuous Subcutaneous Infusion Devices." is seen as one of major influencing trends for Subcutaneous Infusion Devices Market during projected period 2021-2027.
Insulin Infusion Pumps segment in Global market to hold robust market share owing to "The Rising Healthcare Expenditure Related to Diabetes and Favourable Reimbursement Policies for Insulin Pumps are Driving the Growth of the Continuous Subcutaneous Infusion Devices Market.".
Retail Pharmacies dominated the Subcutaneous Infusion Devices market with a share of 46.0% in 2021. This is attributable due to "The Rising Healthcare Expenditure Related to Diabetes and Favourable Reimbursement Policies for Insulin Pumps are Driving the Growth of the Continuous Subcutaneous Infusion Devices Market."
dominated the Subcutaneous Infusion Devices market. This is attributable to growing trend of "Technological Advancements Including AI and the Internet of Things (IoT) are also Boosting the Demand for Continuous Subcutaneous Infusion Devices."

Know More About Global Subcutaneous Infusion Devices Market Report?